Introduction: The Thoratec Corporation has over 10,000 patients registered as recipients of the HeartMate II left ventricular assist device (LVAD) worldwide. Although it has undoubtedly prolonged the lifespan of heart failure patients, the most recognized risk associated with these devices is the development of thrombus. In the presence of a small or developing clot, the HeartMate II display module and system monitor indicate that there is a decrease in pump flow, adjusts its pump power and is accompanied by audible and visual alarms when flow rates drop below a fixed threshold established by Thoratec. In contrast, when thrombus completely inhibits flow through the device, the display module and system monitor have failed in previous case studies to indicate that flow has reduced to zero and do not produce any corresponding alarms. Methods: To test the efficacy of the HeartMate II alarms, a cardiovascular simulation tank was used to reproduce the hemodynamics of a typical heart failure patient. The hemodynamics were then improved by the addition of the HeartMate II LVAD and different partial and complete occlusions were applied to the inlet and outlet of the HeartMate II pump. Conclusions: Partially occluding the inflow and/or outflow of the HeartMate II did display changes in flow and presented with alarms when flow was estimated to be below 2.5 L/min; however, complete occlusion of the inflow and/or outflow failed to produce any alarms or accurately measured changes in flow.
Introduction
Studies have shown that survival can significantly be prolonged in left ventricular heart failure patients who are supported by the HeartMate II (HMII) (Thoratec Inc., Pleasenton, CA) left ventricular assist device (LVAD) in comparison to individuals who are only treated by drug therapy or are unable to receive a heart transplant; however, its use has been associated with several reports of technological issues and elevated risk for thrombotic events. 1 Defining a universal treatment plan for the anticoagulation of HMII recipients continues to be a challenge due to the variability of individuals in response to the same anticoagulation drug therapy. 2 Therefore, it is important that clinicians are diligent about evaluating patients for existing thrombotic events. The occurrence of thrombus is typically assessed by aberrations of performance data estimated by the HMII display module. Unfortunately, this poses a challenge for the clinician because previous case studies have shown this estimation to be unreliable.
HMII pump thrombosis has been estimated to occur at a rate of 6-12%. 3 For example, the University of British Columbia reported the failure of a HMII device due to complete pump thrombosis without any concerning changes in flow, pump power or rotations per minute (RPM) from the HMII display module. Thrombosis was suspected, based on hemodynamic changes of the patient. It was not until transesophageal echocardiography was performed that they revealed there was complete blockage of flow through the device due to thrombus. 3 Another case study from the University of Virginia College of Medicine examined the occurrence of early post-implant thrombus formation due to inadequate anticoagulation. Thrombus became suspected approximately 2 to 3 weeks postoperatively, with no notable changes in flow, pump power or RPM. The patient was identified as having possible pump thrombosis due to hematuria and dyspnea, increasing d-dimers and rapid hemodynamic decline. 4 Unfortunately, in cases such as these, complete occlusion is not detected until the patient begins to show hemodynamic decline and re-emerging symptoms of left ventricular heart failure.
This study hopes to provide a reproducible evaluation of the HMII pump flows and alarms in a controlled laboratory setting with the use of a cardiovascular simulator. In this manner, the hemodynamic characteristics of a left ventricular heart failure patient are recreated and, subsequently, improved with the addition of the HMII. By recreating this clinical scenario, perhaps clinicians can come to a better understanding of the mechanism of the HMII in order to make a prompt diagnosis of pump thrombosis before patients begin to decompensate and long-term damage ensues.
Materials and Methods

Laboratory design
The experiment was performed with a water-filled Donovan Mock Circulation tank located at the University of Arizona Medical Center's Artificial Heart Department. Seventy-milliliter Total Artificial Heart (TAH) ventricles and driver (SynCardia Systems Inc., Tucson, AZ) were integrated into the Donovan Mock in order to generate circulation within the system (Figure 1 ). The simulation tank contained a built-in flowmeter to measure the actual flow rates that were generated within the system in addition to the measurements of left cardiac output measured by the TAH.
Four chambers exist in the Donovan Mock and represent systemic right atrial pressure, left atrial pressure, pulmonary artery pressure and aortic pressure. 5, 6 Each chamber was attached to a pressure transducer in order to continuously measure the relative hemodynamic status of each chamber and are simultaneously displayed on a hemodynamic monitor. Central venous pressure was adjusted within the Mock by adding air to increase the chamber pressure, simulating an increase in volume and/or systemic pressures. Adversely, pressure was relieved in the chambers by opening a valve to release air in order to simulate a decrease in blood volume and/or systemic pressures. The HMII, along with the controller with software version V4.16, was also integrated within the circuit and was connected to the inflow and outflow of the left TAH ventricle (Figure 2 ).
Creation and correction of heart failure
The simulation tank was first adjusted to simulate the healthy hemodynamics of a patient before going into heart failure and replicated multiple times in order to establish reproducibility of the study design. The desired hemodynamics were created by adjusting the settings on the TAH: by adjusting the left and right drive pressures, heart rate and vacuum. The left ventricular function was then diminished to simulate heart failure. The HMII inflow and outflow conduits were then opened to the mock circulatory system and flow was established and adjusted until the hemodynamics improved (Table 1) .
Simulating thrombus development
Once the heart failure model's hemodynamics were adequately corrected with the addition of the HMII, different occlusions were applied to both the inflow and outflow of the left ventricular assist system (LVAS) in order to produce an occlusion. Several combinations of occlusions were evaluated by applying tubing clamps in different locations on the HeartMate II inflow and outflow tracts. They were also placed at different angles and varying percentages of tubing occlusions. Occlusions were measured at four different approximate percentages of the tubing diameter: 25, 50, 75 and 100 ( Figure  3 ). Changes in hemodynamics, pump power and flow, measured by the HMII display module, TAH and the simulator flowmeter, were all recorded for every occlusion scenario. Any alarms and the time until the alarms occurred were also recorded ( Figure 4 ).
Statistics
Statistical analysis was done using Data Analysis and Statistical Software Stata 11 (StataCorp LP, College Station, TX, USA). An independent two-sample t-test was used to identify any significant differences between the pump flows as measured by the HMII and the pump flow measured from the laboratory simulation tank flowmeter.
Results
Pump occlusions and clamp angles
Thirty-nine different combinations of occlusions were evaluated. Angling of the tubing clamp included perpendicular occlusions to the tubing and 60° and 120° occlusion angles. Varying the angle of the applied occlusion clamp did not affect the efficacy of the alarms occurring when the display module detected flow below 2.5 L/min and the angles of the clamp did not significantly alter the power required to maintain the device at 9800 RPM (p>0.05).
Perpendicular occlusions by 25% of the tubing diameter always corresponded with a decrease in pump power as well as a decrease in the flow rate, while RPM were maintained. Similarly, pump power decreased even more at 50% occlusion and resulted in decreased flows through the HMII; RPM were unaffected. Pump power even decreased further with 75% occlusion, again correlating with decreases of flow through the device; however, the pump power increased slightly at 100% occlusion in comparison to 75% tubing occlusion. The power required to maintain the speed of the HMII was inversely related to the degree of occlusion applied to the inflow and outflow conduits of the device, except for complete occlusion of the tubing where the display module estimated a slight increase in pump power. This increase in pump power, however, is still considerably less than the original pump power measured by the display module when no occlusion is present. Due to the variability of pump power and flows, relevant data was primarily analyzed at 50% occlusions perpendicular to the inflow and outflow conduits for consistency and reproducibility of the results. The cardiovascular simulation tank consisted of 4 chambers. These chambers represented the following pressures of the cardiovascular circulatory system: right atrial, left atrial, aortic and pulmonary artery pressure. Each chamber is connected to a pressure transducer for instantaneous data collection. In addition to the TAH, the Thoratec HeartMate II was also integrated into the system by conduits from the inflow and to the outflow of the left TAH ventricle. Software version V4.16 was used. 
Evaluation of flow
The flows measured by the display module did not correlate well to actual cardiac output. Actual pump flows were determined by the difference between the total cardiac output measured by the Donovan Mock and the left cardiac output measured by the TAH. When complete occlusion was placed on the device despite inflow and/ or outflow positions, the display module always registered a flow of 2.8 L/min although zero flow was actually passing through the device. The actual HMII display module's flows in the presence of partial occlusion did not correlate well with the actual flows generated by the device (p>0.01).
In all situations where the HMII measured a flow less than 2.5 L/min in the presence of a partial occlusion on the inflow and/or outflow conduits, the HMII indicated a "Low Flow" alarm on the display module. This alarm occurred 10 seconds after the initiation of the occlusion followed a visual red "Broken-Heart" alarm as well as a continuous audible tone by the system monitor occurring at 20 seconds after the occlusion. The alarms subsided only after the partial occlusion was removed and flow registered above 2.5 L/min on the HMII display module. Any occlusions that were not enough to drop the flow below 2.5 L/min did not trigger any alarms, despite actual flows being below this value ( Table 2 ). The average difference between actual flow and the HMII calculated flow was 0.4 L/min ± 0.37 L/min. If a growing occlusion was simulated by increasing the percentage of inflow occlusions over time, the alarms only triggered when the flow fell below 2.5 L/min on the HMII; however, once the occlusion reached 100%, where actual flow through the device was measured as zero, all alarms, both visual and audible, disappeared after 1 second and a flow of 2.8 L/min appeared on the display module ( Figure 3 ). The HeartMate II inflow was occluded at increasing percentages over time. After each occlusion, the system was allowed to equilibrate for 30 seconds to allow sufficient time for the presentation of alarms. Alarms only presented at 75% occlusion. All pre-existing alarms terminated at 100% occlusion and the display monitor estimated a flow of 2.8 L/min although the actual pump flow was 0 L/min. The same test was done on the outflow conduit with similar results. 
Heartmate II LVAS pump power
Retrograde flow through the HMII was also studied by removing the power supply to the pump and allowing passive flow to occur while the TAH was still functioning at its original heart failure settings. Cardiac output measured by the flowmeter in the Donovan Mock decreased from 5.2 L/min to 3.7 L/min, while the TAH left cardiac 
Discussion
In all cases of complete occlusion of the inflow and/or outflow, the HMII display module failed to indicate that the flow had dropped to zero. This is due to the algorithm used to calculate the pump flow, since flow is estimated indirectly. Flow is estimated by the measured pump speed (RPM) and the power [Power = Work/ Time] required to maintain the HMII axial pump's RPM. Flow inaccuracies were also found in the presence of partial or even non-existent occlusions. Pump flows are based on the pump power and RPM of the HMII device; however, flows shown on the display module were not consistent with actual flows measured by the flowmeter in the Donovan Mock. In a study including 20 patients by Slaughter, et al., HMII pump flows were directly measured intra-operatively in order to examine flow accuracy, utilizing an ultrasonic flow probe on the outside of the device outflow graft. Between flows of 4 to 6 L/minute, which are clinically common operating values, they found a difference of 15-20% between the correct flow and the display module's estimated flow. As a result, they have determined to rely mainly on the trends of the device versus relying on the estimated flow of the display module. 6 The human heart will try to maintain flow despite changes in afterload, which may often be detrimental to the function of the heart in cases of chronically elevated afterload, such as heart failure. The axial flow pump in the presence of complete occlusion, however, will still have normal function of its mechanical components and simply rotate against a static volume of fluid caused by complete thrombosis of the inflow or outflow of the pump, while maintaining the RPM at a normal value without the need to increase work. The increase in pump power from 75% occlusion to 100% occlusion may be explained due to the LVAS overcoming an increase in friction. Because RPM do not change in order to maintain speed, this causes a decrease or complete inhibition of HMII flow and less work is done to maintain the same speed due to the lack of excess force required to move the fluid. (Axial Pump Work = Force/ Distance). 7 To make things more complicated, the HMII power decreases in response to increases in resistance, which seems counter-intuitive to clinicians. This is due to their understanding of the mechanics of the human heart which acts as a volume-displacement pump and increases work in the presence of resistance in order to maintain cardiac output [W=P x dV/dT]. This is evident in the data represented in Table 2 , where pump power decreased in the presence of increasing resistance, up until complete occlusion had occurred. This decrease has been thoroughly explained from a fluid mechanics and mathematical perspective in a study by Arnold, et al. 7 The same study also experimentally found that occluding flow into the HMII corresponds with a decrease in pump power.
Based on the data collected in this study, the development of occlusion, which may represent a thrombus that does not completely inhibit the HMII pump, is accompanied by decreased flow outputs as measured by the display module; however, if thromboemboli acutely migrate into the device inlet and occlude the flow, this results in an immediate blockage of flow through the device, without any indication by the display module of changes in flow, RPM or pump power. Both of these situations have been clinically encountered. 8 In this study, gradual occlusion, representing growing clot at the inflow of the device, resulted in continuously decreasing flows as well as presenting audible and visual alarms after the flows dropped below 2.5 L/min. Unfortunately, this replication of acute thrombosis formation leading to complete blockage at the inflow of the device was not accompanied by any significant changes in display module power, except for declining hemodynamic changes. Complete inhibition of flow is a life-threatening event that requires immediate treatment. However, it can be undetectable to the clinician if they are looking at the display module data alone.
Conclusion
Pump thrombus occurs in 6-12% of the recipients; however, complete replacement of the HMII has been associated with low mortality rates. 4, 8 This solution is costly to the patient, but provides complete certainty that the thrombus has been removed. Other studies have shown that the use of eptifibatide can be effective in treating thrombosis non- surgically. 9 Despite the route of treatment, intervening in a timely manner may prevent extensive end-organ damage due to the re-establishment of decompensated left ventricular heart failure. Further research should be dedicated to detecting pump thrombosis pro-actively so that treatment can be given as soon as possible.
The algorithm used to calculate flow generated by the HMII is solely an estimation. Although this estimation may sometimes be within range of true device output, it is best to use it clinically as an evaluation of flow trends over time. If hemodynamics in a HMII recipient begin to decline, the device may need to be examined for possible thrombosis or needs to have a clinician increase or decrease its RPM. Unfortunately, it can be difficult to distinguish between inadequacies of the device versus treatment that may directly be needed by the patient. Changes in device RPM should not be made to compensate for issues that require an alteration in medical and pharmacological management of the patient, such as hyper-or hypovolemia, hypertension, pulmonary hypertension or right-sided heart failure. Further research is required in order to determine a more accurate marker for thrombus. This may include the regular assessment of the hemolysis that is often associated with pump thrombus, especially in out-patients who are coming into the clinic for followup. This may help clinicians detect thrombus, partial or complete, before heart failure symptoms re-appear; however, the only reliable measurement of flow through the device today is through transesophageal echocardiography or right heart catheterization. 9 Clinicians often use pump power to detect thrombotic events in the HeartMate II; however, it is important that the clinician remain cognizant of the different mechanisms of the native heart versus an axial flow pump. This is rather challenging since the HeartMate II decreases power in response to increases in resistance, which is counter-intuitive to clinicians who are used to the opposite being true for the native heart. Although the pump power may not seem significantly higher, the flow may appear as generally unchanged or within acceptable limits when there is complete blockage of flow through the device. Complete thrombosis is a lifethreatening situation and requires immediate medical intervention. The clinician should not only be attentive to the trends of the device, but also always be aware of any physiological or symptomatic changes in the patient, especially if they are portraying signs of left ventricular heart failure.
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